* If you want to update the article please login/register
Background: The effectiveness of olaparib in homologous recombination repair mutated metastatic castration-resistant prostate cancer has been shown by randomized trial results, according to phase III of the prostate cancer treatment program. The next-generation hormonal agent progression was confirmed by randomized trial results. In mCRPC patients receiving prior chemotherapy with docetaxel, a randomised double-blind Phase II trial, which evaluated olaparib and abiraterone versus placebo and abiraterone in randomized double-blind Phase II research. The investigation used tumor, blood, and circulating tumor DNA testing to determine patient HRRm status, but tumor tissue collection and DNA sequencing success rates were not representative of real-world testing, resulting in modest tissue acquisition and DNA sequencing success rates that were not representative of real-world testing. Patients and methods (PotDNA) analysis of patient response to treatment The study of germline and ctDNA samples was used to determine HRRm status more accurately and quantitatively determine patient response to therapy. Patients with mCRPC benefit from the combination of olaparib and abiraterone therapy, regardless of HRRm status.
Source link: https://europepmc.org/article/MED/34830984
Plasma tumor DNA is a potential early noninvasive biomarker of therapy success in metastatic castration-resistant prostate cancer. Herein, we investigated whether pretreatment ptDNA levels reflect metabolic tumour burden in mCRPC and help anticipate treatment outcomes in combination with functional imaging. Targeted next-generation sequencing was used to determine the ptDNA fraction from 102 mCRPC patients receiving abiraterone or enzalutamide, according to a target. Multiple experiments revealed that ptDNA, MTV, and serum lactate dehydrogenase, as well as visceral metastasis in the training cohort were independent predictors of both OS and PFS. Prognostic scores were generated, with the identification of three groups of patients with significantly different median OS and PFS probabilities. In the validation cohort for both OS and PFS, the difference in median survival among risk groups was confirmed. In our research, we found that combining plasma DNA analysis with functional imaging may increase prognostic risk stratification and treatment selection in mCRPC.
Source link: https://europepmc.org/article/MED/34657387
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions